Rejection After Auxiliary Partial Orthotopic Liver Transplantation: An Exploratory Comparison by Native-Liver Cirrhosis Status
Key facts
- Who runs it
- Zhi-Jun Zhu
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 44 people enrolled
- Started
- 1 Dec 2025
- Ended
- 30 Jun 2026
- Type of study
- Observational, 2 groups
- Record updated
- 2 November 2026
Who can take part
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Recipients who underwent auxiliary partial orthotopic liver transplantation (APOLT) at Beijing Friendship Hospital, Capital Medical University, between 2014 and 2025
- Patients with a confirmed underlying liver disease
- Patients without a history of previous solid-organ transplantation
- Patients with available histopathological examination of native-liver tissue obtained during the initial APOLT procedure, allowing classification of native-liver cirrhosis status
- Patients with sufficient clinical records and follow-up information to establish baseline characteristics, operative variables, and the occurrence and timing of the primary outcome or the applicable censoring time
Who cannot take part
- Patients who underwent APOLT for acute or subacute liver failure
- Patients with idiopathic portal hypertension without histopathological evidence of cirrhosis
- Patients with insufficient clinical or follow-up data to determine eligibility, classify native-liver cirrhosis status, or assess the primary outcome
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This retrospective single-center cohort study aims to investigate the association between native-liver cirrhosis status and post-transplant outcomes in recipients undergoing auxiliary partial orthotopic liver transplantation (APOLT). A total of 44 recipients who underwent APOLT between 2014 and 2025 will be included and classified into non-cirrhotic and cirrhotic groups according to the histopathological findings of the retained native liver. The study will compare biopsy-proven rejection, including first and recurrent rejection episodes, postoperative complications, overall survival, and graft survival between the two groups. The findings may help improve understanding of the relationship between native-liver cirrhosis status and post-transplant outcomes and provide evidence for future clinical research and individualized post-transplant management.
The 2 groups in the trial
- Non-cirrhotic native liver
Recipients undergoing APOLT whose retained native liver showed no histopathological evidence of cirrhosis. A total of 11 recipients were included in this cohort. Outcomes were assessed retrospectively based on medical records, including biopsy-proven rejection, postoperative complications, overall survival, and graft survival.
- Cirrhotic native liver
Recipients undergoing APOLT whose retained native liver showed histopathological evidence of cirrhosis. A total of 33 recipients were included in this cohort. Outcomes were assessed retrospectively based on medical records, including biopsy-proven rejection, postoperative complications, overall survival, and graft survival.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Record updated
- 2 November 2026